Aldeyra Therapeutics Inc (NASDAQ: ALDX)’s stock price has increased by 2.36 compared to its previous closing price of 2.12. However, the company has seen a 13.02% increase in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-15 that NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ:ALDX). Investors who purchased Aldeyra securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALDX.
Is It Worth Investing in Aldeyra Therapeutics Inc (NASDAQ: ALDX) Right Now?
Moreover, the 36-month beta value for ALDX is 1.05. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALDX is 57.98M and currently, short sellers hold a 6.12% of that float. On April 15, 2025, ALDX’s average trading volume was 1.41M shares.
ALDX’s Market Performance
ALDX’s stock has seen a 13.02% increase for the week, with a -65.61% drop in the past month and a -53.83% fall in the past quarter. The volatility ratio for the week is 14.41%, and the volatility levels for the past 30 days are at 15.27% for Aldeyra Therapeutics Inc The simple moving average for the past 20 days is -49.63% for ALDX’s stock, with a -57.41% simple moving average for the past 200 days.
Analysts’ Opinion of ALDX
Many brokerage firms have already submitted their reports for ALDX stocks, with Oppenheimer repeating the rating for ALDX by listing it as a “Outperform.” The predicted price for ALDX in the upcoming period, according to Oppenheimer is $10 based on the research report published on April 03, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $10. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 02nd, 2024.
H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $15 in the report published on April 27th of the previous year.
ALDX Trading at -60.71% from the 50-Day Moving Average
After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.86% of loss for the given period.
Volatility was left at 15.27%, however, over the last 30 days, the volatility rate increased by 14.41%, as shares sank -67.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.70% lower at present.
During the last 5 trading sessions, ALDX rose by +11.20%, which changed the moving average for the period of 200-days by -37.21% in comparison to the 20-day moving average, which settled at $4.31. In addition, Aldeyra Therapeutics Inc saw -56.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALDX starting from PERCEPTIVE ADVISORS LLC, who sale 3,400,000 shares at the price of $1.42 back on Apr 03 ’25. After this action, PERCEPTIVE ADVISORS LLC now owns 5,875,851 shares of Aldeyra Therapeutics Inc, valued at $4,828,000 using the latest closing price.
Machatha Stephen, the Chief Development Officer of Aldeyra Therapeutics Inc, sale 16,041 shares at $4.74 during a trade that took place back on Aug 12 ’24, which means that Machatha Stephen is holding 236,771 shares at $75,975 based on the most recent closing price.
Stock Fundamentals for ALDX
Current profitability levels for the company are sitting at:
- -245.85 for the present operating margin
- 0.5 for the gross margin
The net margin for Aldeyra Therapeutics Inc stands at -228.41. The total capital return value is set at -0.7. Equity return is now at value -58.54, with -44.16 for asset returns.
Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.82. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -31.21.
Currently, EBITDA for the company is -60.12 trillion with net debt to EBITDA at 0.73. When we switch over and look at the enterprise to sales, we see a ratio of 365.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.48.
Conclusion
To wrap up, the performance of Aldeyra Therapeutics Inc (ALDX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
